Timing from MOLST form completion, palliative care referral, and hospice enrollment to death in patients with AML and MDS
| . | AML . | MDS . |
|---|---|---|
| Time from MOLST to death, in days [n = 294, (IQR)] | 14.5 (47.0) | 37.0 (178.0) |
| Time from palliative care referral to death, in days [n = 204, median (IQR)] | 14.0 (46.0) | 12.0 (52.0) |
| Time from palliative care visit to death, in days [n = 198, median (IQR)] | 11.0 (42.0) | 12.0 (49.0) |
| Time from hospice enrollment to death, in days [n = 160, median (IQR)] | 5.0 (6.0) | 4.0 (10.0) |
| . | AML . | MDS . |
|---|---|---|
| Time from MOLST to death, in days [n = 294, (IQR)] | 14.5 (47.0) | 37.0 (178.0) |
| Time from palliative care referral to death, in days [n = 204, median (IQR)] | 14.0 (46.0) | 12.0 (52.0) |
| Time from palliative care visit to death, in days [n = 198, median (IQR)] | 11.0 (42.0) | 12.0 (49.0) |
| Time from hospice enrollment to death, in days [n = 160, median (IQR)] | 5.0 (6.0) | 4.0 (10.0) |
AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MOLST, Medical Orders for Life-Sustaining Treatment.